

Teleprinter operator services
 Traffic census counts
 Training, tuition or education
 Translation services
 Transport research of the kind normally carried out for the
 Department of Transport
 Travel services

Travel and transport surveys
 Typing, secretarial and clerical services
 Vehicle excise duty refunds
 Waste disposal services
 Welfare services
 Welfare food distribution under special Department of Health
 scheme (10 SI)

DEPARTMENT OF HEALTH

MEDICINES CONTROL AGENCY

Market Towers, 1 Nine Elms Lane, London SW8 5NQ.
 Telephone 0171-273 0422, or 0425

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Product Licences Authorised Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
00014/0430	The Boots Company Plc	Throcaïne Sore Throat Spray	Lidocaine Hydrochloride 2.000 wv	For the symptomatic relief of severe sore throats. Pharmacy Medicine	26th January 1996
00014/0464	The Boots Company Plc	First Aid Antiseptic Liquid	Cetylpyridinium Chloride -025 wv	For the treatment of cuts, grazes, insect bites and stings, boils, spots and pimples. For the relief of symptoms of sore throats including those associated with colds and flu. For the relief of mouth infections and daily oral hygiene. For the relief of minor burns and scalds and small areas of sunburn. General Sales List	23rd January 1996
00014/0519	The Boots Company Plc	Children's Pain Relief Syrup 3 Months Plus	Paracetamol Micronised 2.400 wv	To relieve pain and reduce fever in many conditions including headache, toothache, teething, feverishness, colds and influenza. Pharmacy Medicine	22nd January 1996
00017/0354	Astra Pharmaceuticals Ltd	Foscavir	Foscarnet Sodium Hexahydrate 24.000 mg	For induction and maintenance therapy of cytomegalovirus (CMV) retinitis in patients with AIDS. Induction therapy of mucocutaneous Herpes Simplex Virus (HSV) infections, unresponsive to acyclovir in immuno compromised patients. Prescription Only Medicine.	5th January 1996
00017/0358	Astra Pharmaceuticals Limited	Entocort CR 2.25 mg Capsules	Budesonide Micronized 2.250 mg Budesonide Micronized 2.250 mg	Entocort CR Capsules are indicated for the induction of remission in patients with mild to moderate Crohn's disease affecting the ileum and/or the ascending colon. Prescription Only Medicine.	31st January 1996
00017/0359	Astra Pharmaceuticals Limited	Entocort CR 3 mg Capsules	Budesonide Micronized 3.000 mg Budesonide Micronized 3.000 mg	Entocort CR Capsules are indicated for the induction of remission in patients with mild to moderate Crohn's disease affecting the ileum and/or the ascending colon. Prescription Only Medicine.	31st January 1996
00031/0396	Roche Products Limited	Roferon-A Vials, 3 million I.U.	Interferon Alfa-2a (rbe) 3.000 mu	(1) Hairy cell leukaemia. (2) AIDS-related Kaposi's sarcoma in patients without history of opportunistic infection. (3) Chronic phase Philadelphia-chromosome positive chronic myelogenous leukaemia. It is still unknown whether Roferon®-A can be considered as a treatment with a curative potential in this indication. (4) Cutaneous T-cell lymphoma. Interferon alpha-2A (Roferon®-A) may be active in patients who have progressive disease and who are refractory to, or unsuitable for, conventional therapy. (5) Adult patients with chronic active hepatitis B who have markers for viral replication, i.e., those who are positive for HBV-DNA, DNA polymerase or HBeAg. (6) Adult patients with chronic hepatitis C who are positive for HCV antibodies, have elevated serum alanine aminotransferase (ALT) and without liver decompensation (and there is no evidence of long term benefit on clinical and histological grounds). (7) Recurrent or metastatic renal cell carcinoma. (8) Follicular non Hodgkin's lymphoma. Prescription Only Medicine	12th January 1996
00031/0397	Roche Products Limited	Roferon-A Vials, 4.5 million I.U.	Interferon Alfa-2a (rbe) 4.500 mu	(1) Hairy cell leukaemia. (2) AIDS-related Kaposi's sarcoma in patients without history of opportunistic infection. (3) Chronic phase Philadelphia-chromosome positive chronic myelogenous leukaemia. It is still unknown whether Roferon®-A can be considered as a treatment with a curative potential in this indication. (4) Cutaneous T-cell	12th January 1996